# A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

> **NCT06413615** · PHASE2 · RECRUITING · sponsor: **Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** FDA022-BB05

## Key facts

- **NCT ID:** NCT06413615
- **Lead sponsor:** Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2025-07-31
- **Final completion:** 2026-06-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2024-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413615, "A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06413615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*